The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

This innovative CBGM system, designed for continuous, accurate glucose monitoring over three years without any on-body external component, offers a more convenient and less intrusive alternative ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack has cleared the first human clinical study of its long-term continuous glucose monitoring implant, designed to ...

Glucotrack’s CEO Paul V. Goode told Medical Device Network: "In a survey of 757 patients, we found significant interest in an implantable continuous glucose monitor. The most appealing features ...

Germantown, Maryland Monday, February 10, 2025, 16:00 Hrs [IST] ...

Goode, expressed enthusiasm about the results, indicating that this technology brings continuous glucose monitoring closer to reality. The CBGM is designed to be a long-term implantable device ...

The CBGM is a long-term implantable device with no on-body external component, designed for three years of continuous, accurate blood glucose monitoring, offering a more convenient and less ...

implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense ® 365 CGM system. Eversense 365 is the ...